Janux Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Janux Therapeutics Inc
Access all reports
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to create targeted therapies that activate the immune system specifically within the tumor microenvironment, minimizing systemic side effects. Janux Therapeutics is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
JANX
Country
🇺🇸 United States